Creative Planning
BMRN icon

Creative Planning’s BioMarin Pharmaceuticals BMRN Stock Holding History

Creative Planning’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,800
Closed -$22K – 3993
2014
Q2 		$22K Buy
+2,800
New +$169K ﹤0.01% 2423

Other funds holding BMRN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
ARGA Investment Management
ARGA Investment Management Stamford, Connecticut $3.94B AUM 28.9% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Creative Planning's BMRN Position: Q3 2026 in Review

Creative Planning increased its BioMarin Pharmaceuticals (BMRN) stake by 19% in Q3 2026, buying an estimated $1.84M and bringing the position to 182,410 shares worth $10.9M. The position accounts for 0.01% of the portfolio, ranked #906.

Creative Planning first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. 271 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Creative Planning held 182,410 shares of BioMarin Pharmaceuticals worth $10.9M as of Q3 2026.
  • Creative Planning bought 29,249 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $1.84M.
  • BioMarin Pharmaceuticals made up 0.01% of Creative Planning's portfolio in Q3 2026, its #906 holding.
  • Creative Planning first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 271 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.